Spark Biopharma
Harnessing image-based screening and target protein identification to accelerate innovative drug development.
Harnessing image-based screening and target protein identification to accelerate innovative drug development.
Spark Biopharma is a biotechnology startup founded in 2016 at Seoul National University. The company specializes in harnessing image-based screening and target protein identification to expedite the development of innovative drugs. Leveraging proprietary drug molecule diversity technology and a unique fluorescent skeleton probe, Spark Biopharma is dedicated to identifying and developing novel drug candidates. The company recently received a KRW25.00B Series C investment on April 4, 2022, with notable investors including Company K Partners, KB Investments, IMM Investment, Timefolio Asset Management, WE Ventures, Medytox Venture Investment, Shinhan Venture Investment, Kiwoom Investment, DAOL Investment & Securities, and Dt& Investment. With a focus on strategic collaborations with both domestic and international research institutes and pharmaceutical organizations, Spark Biopharma aims to accelerate drug development speed and success rates in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | KRW25.00B | 10 |
|
04 Apr 2022 |
| Series B | KRW3.00B | - | 25 Nov 2021 | |
| Venture Round | Unknown | - | 01 Jan 2018 |
No recent news or press coverage available for Spark Biopharma.
We care about your data, and we'd love to use cookies make your experience better.
